In The News: Interview

Home / In The News / In The News: Interview

“While SIWA’s focus remains on developing a powerful therapeutic for aggressive cancers, the Covid-19 pandemic presented us with an opportunity to explore how 318H could also be used to treat infectious diseases.”

In this interview, our CEO and Chief Scientific Officer, Lewis Gruber, discusses the results of our recent preclinical tests, which confirmed 318H shows promise to become both a comprehensive cancer therapy and a broad-spectrum antiviral drug.

We are pleased that our monoclonal antibody SIWA 318H shows promise to be developed into a broad-spectrum antimicrobial drug as well as a comprehensive cancer therapy. We believe 318H has the potential to treat a wide variety of infectious diseases and to provide a powerful therapeutic to support patients who recover from COVID-19 but then suffer from long term complications

Read the full interview here: